Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-Rabies Biological is a novel research-stage biological agent being developed by Mediclone Biotech for the prophylaxis of rabies. The program is supported by the Department of Science & Technology, Government of India (project reference VI-D&P/234/0708/TDT). While Mediclone Biotech currently markets a traditional Anti Rabies Serum (ARS), this project represents a next-generation approach to rabies prevention, likely focusing on the neutralization of the rabies virus to prevent its entry into the central nervous system. The candidate is currently in the preclinical stage of development and is intended for post-exposure or pre-exposure prophylaxis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Anti-Rabies Biological.